Telomir Pharmaceuticals (NASDAQ:TELO) is a biotechnology company focused on the discovery and development of telomerase–targeted immunotherapies designed to treat oncology and chronic respiratory diseases. The company’s proprietary platform leverages the universal expression of telomerase reverse transcriptase (hTERT) in tumor cells to stimulate the patient’s immune system to recognize and destroy malignant cells. By harnessing a DNA‐based vaccine approach, Telomir aims to create durable, antigen‐specific immune responses that may complement existing cancer treatments, including checkpoint inhibitors and chemotherapeutics.
Telomir’s lead product candidate, VTX‐001, is a first‐in‐class hTERT immunotherapy currently in Phase I/II clinical trials for solid tumors such as non‐small cell lung cancer and ovarian carcinoma. An additional pipeline asset, VTX‐R, is being investigated for fibrotic and inflammatory lung conditions, including idiopathic pulmonary fibrosis (IPF). Both programs are supported by preclinical data demonstrating favorable safety profiles and T-cell activation against telomerase‐expressing cells. The company collaborates with academic institutions and contract research organizations to advance its clinical stage assets and explore combination strategies with other immune-modulating agents.
Founded in 2007 and headquartered in San Diego, California, Telomir maintains research partnerships in North America and Europe to facilitate patient enrollment and translational studies. The company’s R&D operations encompass molecular biology, immunology, and clinical development teams working in coordinated laboratory and clinical settings. Through strategic collaborations and licensing agreements, Telomir has strengthened its intellectual property portfolio and extended its global reach, positioning itself to address high‐unmet needs in oncology and chronic respiratory diseases.
Telomir is led by a seasoned management team with extensive experience in biotechnology and pharmaceutical development. The executive leadership includes professionals with backgrounds in immuno-oncology research, clinical trial design, regulatory affairs, and commercial strategy. Guided by a commitment to innovation and patient‐centered outcomes, the company continues to expand its pipeline, explore new indications for its telomerase‐based platform, and forge partnerships that can accelerate the translation of its therapies from bench to bedside.
